Shelter Pharma

Which are the latest news on Shelter Pharma?

Why is Shelter Pharma Ltd falling/rising?

As of 05-Sep, Shelter Pharma Ltd's stock price is rising to 31.60, reflecting a positive shift in investor sentiment after a trend reversal. Despite a year-to-date decline of 14.01%, increased trading activity and current price levels above several moving averages suggest a potential recovery phase.

As of 05-Sep, Shelter Pharma Ltd's stock price is rising, currently at 31.60, reflecting an increase of 0.23 (0.73%). This upward movement follows a trend reversal after two consecutive days of decline. The stock has outperformed its sector by 1.18% today, indicating a positive shift in investor sentiment. Additionally, there has been a significant increase in investor participation, with delivery volume rising by 94.44% compared to the 5-day average, suggesting heightened interest in the stock. <BR><BR>Despite a challenging year-to-date performance, where the stock is down 14.01%, the recent gains and positive trading activity indicate a potential recovery phase. The stock's current price is higher than its 20-day, 50-day, and 100-day moving averages, although it remains below the 5-day and 200-day moving averages. This mixed moving average performance suggests that while there is short-term volatility, the stock may be finding support at current levels, contributing to its rise today.

What does Shelter Pharma do?

Shelter Pharma Ltd is a micro-cap pharmaceutical company focused on manufacturing ayurvedic and herbal products, with a market cap of INR 55 Cr. It has a P/E ratio of 6.00 and a dividend yield of 0.62%, but no recent sales or profit data is available.

Overview:<BR>Shelter Pharma Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, focusing on the manufacturing of ayurvedic and herbal products.<BR><BR>History:<BR>Shelter Pharma Limited was incorporated on 12 October 2007, transitioning from a partnership firm named "M/s Shelter Pharma" to a public limited company. There is no recent sales and profit data reported.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 55 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 6.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.62%<BR>Debt-Equity: 0.00<BR>Return on Equity: 12.43%<BR>Price-to-Book: 0.76<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Shelter Pharma?

Shelter Pharma's peers include Source Natural, Phaarmasia, Biofil Chemicals, and others. Shelter Pharma has average management risk, good growth, and an excellent capital structure, with a 1-year return of -30.00%, better than Mangalam Drugs but worse than Phaarmasia's 192.54%.

Peers: The peers of Shelter Pharma are Source Natural, Phaarmasia, Biofil Chemicals, Mangalam Drugs, Vasundhara Rasy., Parmax Pharma, Kabra Drugs, Vivo Bio Tech, Vilin Bio Med, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Source Natural, while Average management risk is found at Shelter Pharma, Biofil Chemicals, and Vasundhara Rasy., and the rest have Below Average management risk. Growth is Good at Shelter Pharma and Ajooni Biotech, Average at Phaarmasia and Vilin Bio Med, and Below Average at Source Natural, Biofil Chemicals, Mangalam Drugs, Vasundhara Rasy., Parmax Pharma, Kabra Drugs, and Vivo Bio Tech. Excellent capital structure is noted at Shelter Pharma, Good at Source Natural, Biofil Chemicals, and Vasundhara Rasy., while the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Phaarmasia at 192.54%, while the lowest is Mangalam Drugs at -57.20%. Shelter Pharma's 1-year return is -30.00%, which is better than Mangalam Drugs but worse than Phaarmasia. Additionally, the six-month return is negative for Shelter Pharma, Mangalam Drugs, Kabra Drugs, Vivo Bio Tech, and Vilin Bio Med.

When is the next results date for Shelter Pharma Ltd?

The next results date for Shelter Pharma Ltd is 28 May 2026.

The next results date for Shelter Pharma Ltd is scheduled for 28 May 2026.

How has been the historical performance of Shelter Pharma?

Shelter Pharma has shown consistent growth in net sales and profitability, with net sales increasing from INR 30.06 crore in March 2022 to INR 50.66 crore in March 2025, and profit after tax rising from INR 1.84 crore to INR 7.24 crore during the same period. The company's financial performance reflects a strong upward trend across key metrics.

Answer:<BR>The historical performance of Shelter Pharma shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Shelter Pharma's net sales have steadily increased from INR 30.06 crore in March 2022 to INR 50.66 crore in March 2025. This growth is accompanied by a rise in total operating income, which reached INR 50.66 crore in March 2025, up from INR 30.06 crore in March 2022. The company's total expenditure also grew, amounting to INR 40.59 crore in March 2025, compared to INR 27.38 crore in March 2022. Operating profit (PBDIT) has shown significant improvement, rising from INR 2.68 crore in March 2022 to INR 10.08 crore in March 2025, reflecting an operating profit margin of 19.88% in the latest fiscal year. Profit before tax increased from INR 2.51 crore in March 2022 to INR 9.68 crore in March 2025, with profit after tax also rising from INR 1.84 crore to INR 7.24 crore during the same period. The company's total assets grew from INR 12.84 crore in March 2022 to INR 48.30 crore in March 2025, while total liabilities increased from INR 12.84 crore to INR 48.30 crore, indicating a proportional growth in both assets and liabilities. Cash flow from operating activities improved significantly, reaching INR 5.00 crore in March 2025, compared to a negative cash flow of INR 1.00 crore in March 2024. Overall, Shelter Pharma demonstrates a robust upward trend in its financial performance across key metrics.

Has Shelter Pharma declared dividend?

Shelter Pharma Ltd has declared a 3% dividend, with an ex-date of September 23, 2025. While recent total returns show positive growth in the short to medium term, longer-term returns have been stagnant with no dividends declared in the past few years.

Shelter Pharma Ltd has declared a 3% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 3%<BR>- Ex-date: 23 Sep 25<BR><BR>Dividend Yield: 0.67%.<BR><BR>Total Returns by Period:<BR>In the 3-month period, the price return was 9.9%, the dividend return was 0.75%, resulting in a total return of 10.65%.<BR><BR>In the 6-month period, the price return was 3.51%, the dividend return was 0.68%, leading to a total return of 4.19%.<BR><BR>For the 1-year period, the price return was 5.5%, the dividend return was 1.25%, which culminated in a total return of 6.75%.<BR><BR>Over the 2-year period, the price return was -3.95%, the dividend return was 1.32%, resulting in a total return of -2.63%.<BR><BR>In the 3-year period, there was no price return, no dividend return, and thus a total return of 0.0%.<BR><BR>For the 4-year period, there were no changes in price or dividends, leading to a total return of 0.0%.<BR><BR>In the 5-year period, again, there were no returns from price or dividends, resulting in a total return of 0.0%.<BR><BR>Overall, Shelter Pharma Ltd has declared a dividend, and while the recent total returns show positive growth in the short to medium term, longer-term returns have been stagnant with no dividends declared in the past few years.

Is Shelter Pharma overvalued or undervalued?

As of August 28, 2025, Shelter Pharma is considered undervalued with a valuation grade upgrade to very attractive, supported by a low PE ratio of 7.42 and an EV to EBIT of 5.03, significantly lower than its peers like Sun Pharma and Divi's Lab, despite a recent stock price decline.

As of 28 August 2025, Shelter Pharma's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, especially when compared to its peers. Key ratios supporting this assessment include a PE ratio of 7.42, an EV to EBIT of 5.03, and a PEG ratio of 0.46, all of which are substantially lower than industry averages.<BR><BR>In comparison to its peers, Shelter Pharma stands out with a much lower PE ratio than Sun Pharma (33.18) and Divi's Lab (70.66), both of which are classified as expensive. Additionally, Shelter Pharma's EV to EBITDA ratio of 4.89 is significantly more attractive than that of its competitors, reinforcing its undervaluation. Despite a recent decline in stock price, Shelter Pharma has outperformed the Sensex over the past month, suggesting a potential rebound as market conditions stabilize.

How big is Shelter Pharma?

As of 24th July, Shelter Pharma Ltd has a market capitalization of 52.00 Cr, classifying it as a Micro Cap company, with no valid financial data available for Net Sales and Net Profit for the latest four quarters. Shareholder's Funds are 35.82 Cr and Total Assets are 37.88 Cr as of March 2024.

As of 24th July, <BR><BR>Market Cap: Shelter Pharma Ltd has a market capitalization of 52.00 Cr, classifying it as a Micro Cap company. <BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters. <BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 35.82 Cr and Total Assets valued at 37.88 Cr.

Who are the top shareholders of the Shelter Pharma?

The top shareholders of Shelter Pharma include promoters, with Shakil Nisarahmed Sabugar holding the largest stake at 15.23%. Individual investors own 43.24% of the company, and there are no mutual funds or foreign institutional investors involved.

The top shareholders of Shelter Pharma primarily consist of promoters, with Shakil Nisarahmed Sabugar holding the highest stake at 15.23%. Individual investors collectively own 43.24% of the company. There are no mutual funds or foreign institutional investors (FIIs) holding shares in Shelter Pharma, and there are no pledged promoter holdings.

What is the technical trend for Shelter Pharma?

As of May 30, 2025, Shelter Pharma's technical trend is mildly bearish, indicated by daily moving averages and weekly Bollinger Bands, despite a mildly bullish MACD and no clear signals from the RSI or Dow Theory.

As of 30 May 2025, the technical trend for Shelter Pharma has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly Bollinger Bands also reflect a bearish outlook. The MACD on the weekly chart is mildly bullish, but this is countered by the lack of signals from the RSI on both weekly and monthly time frames. Additionally, the Dow Theory shows no trend in both weekly and monthly perspectives. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and weekly Bollinger Bands.